Innovations in MS: Mechanisms of Disease Progression and Immune Reconstitution

Innovations in MS: Mechanisms of Disease Progression and Immune Reconstitution

Innovations in MS: Mechanisms of Disease Progression and Immune Reconstitution
RestartResume
This panel discussion focuses on recent advances in MS disease progression and treatments options for this disease.

Available credits: 0.25

Time to complete: 15 minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Rapid advances in the management of multiple sclerosis reflects an evolving landscape whose emergent treatment philosophies are focused on improving both short- and long-term patient outcomes. This interview reviews different management strategies as well as the importance of personalized treatment, and what they mean for you and your patients. Join Professor Andrew Chan, Professor Tobias Derfuss, and Dr. Gavin Giovannoni as they review management strategies and practical considerations for each and every patient affected by multiple sclerosis.

    This is the first of two discussions recorded at McCann Complete Medical’s special meeting on multiple sclerosis held in Baveno, Italy. Click here to view the second discussion titled The New MS Treatment Landscape: Personalized Management Strategies.

    Disclaimer: Some products discussed in this activity have not received regulatory approval by the US FDA for the treatment of patients with Multiple Sclerosis. The FDA has stated that “good medical practice and the best interests of the patient require that physicians use legally available drugs, biologics and devices according to their best knowledge and judgement.” 

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, The Omnia-Prova Education Collaborative (TOPEC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TOPEC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host: 
    Matt Birnholz
    Vice President and Medical Director
    ReachMD

    Dr. Birnholz has no financial relationships to disclose. 

    Faculty: 

    Andrew Chan, MD
    Department of Neurology, Inseispital
    Bern University Hospital
    University of Bern, Switzerland

    Prof. Chan has disclosed that he is an intellectual property rights/patent holder of Antibodyprofile and Protagen. He receives consulting fees from Bayer, Biogen, Genzyme, Roche and Novartis; fees for non-CME services from Roche and Teva; and contracted research fees from Biogen, Genyzme and Novartis.

    Tobias Derfuss, MD
    Professor of Neurology
    Departments of Neurology and Biomedicine University Clinic
    Basel, Switzerland

    Prof. Derfuss has disclosed he receives consulting fees from Bayer, Biogen Idec, GeNeuro, Genzyme, Merck KGaA, Mitsubishi Pharma, Novartis Pharmaceuticals, Roche, and Schering Pharma. He has also disclosed that his spouse in an employee of Novartis Pharmaceuticals and holds stock options.

    Gavin Giovannoni, MBBCh, PhD, FCP (S.A., Neurol), FRCP, FRCPath
    Blizard Institute, Barts and the London School of Medicine and Dentistry,
    Queen Mary University, London
    Department of Neurology
    Royal London Hospital
    Barts Health NHS Trust

    Dr. Giovannoni has disclosed that he is part of Steering Committees for AbbVie, Biogen-Idec, Novartis, TEVA, Roche; he is a consultant for Biogen-Idec, GW Pharma, Merck-Serono, Novartis, Genzyme Sanofi, Fiveprime, Ironwood, Synthon BV, Vertex Pharmaceuticals; and a clinical advisor for Canbex.

    Reviewers/Planners/Authors:

    • Sean T. Barrett has nothing to disclose.
    • Carole Drexel, PhD has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Lawrence Sherman has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Explain the role of B cells in MS disease progression and its impact on the development of new pharmacologic therapies
    • Discuss the role and safety of selective immune reset and reconstitution therapies for the management of MS
  • Target Audience

    This activity is designed to meet the educational needs of practicing neurologists, and other healthcare professionals that treat patients with multiple sclerosis.

  • Accreditation and Credit Designation Statements

    The Omnia-Prova Education Collaborative, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    The Omnia-Prova Education Collaborative, Inc. designates this enduring material for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 CreditsTM to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at mutualrecognition@uems.eu.

  • Provider

    TOPEC Global designs educational activities based on evidence-based medicine, needs and gaps analyses, learner feedback, and more. Its mission is to serve as an innovative and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.

  • Commercial Support

    This activity is supported by an independent educational grant from Merck KGaA, Darmstadt, Germany.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of TOPEC and TOPEC Global. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of TOPEC Global you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments

Sign-up for the Global Neurology Academy newsletters.
Comprehensive Neurology Education.

Better education for a better you.

* Required
Optional
Register

Join the Global Neurology Academy of learners.
Registration is free and easy.

Register Now